DNTH: SEC Form 144 filed by Dianthus Therapeutics Inc.
Stocks in this Quantisnow insightHealth Care
Historical context for DNTH
Across the 24 sessions after earlier DNTH headlines, the stock closed higher 16 times and lower 8 times, with a median move of 2.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | DNTH | SPY |
|---|---|---|---|
| Aug 5, 2026 | Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results | +1.9% | -0.2% |
| Aug 4, 2026 | Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseasesand 1 other headline that session | +4.1% | +1.8% |
| Jul 6, 2026 | Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4) | -1.1% | +0.9% |
| Jun 29, 2026 | Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis | +0.3% | +1.6% |
| Jun 3, 2026 | Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | +4.2% | -0.7% |
| May 27, 2026 | Dianthus Therapeutics to Participate in Two Investor Conferences | -0.2% | -0.0% |
Quantisnow market dataNASDAQ
DNTH
Dianthus Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2018
Get push alerts for DNTH
Full DNTH profile on Quantisnow Follow DNTH and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time